Due to the Pentecost holidays, we will resume our activity tomorrow, 10 06 2025
Biofarm, (stock symbol BIO), one of the most important drug manufacturers in Romania, ended 2023 with a net profit of about 77 million lei, up 9% from the previous year and a turnover of approx. 280 million lei, according to preliminary results (unaudited).
"In 2023, we successfully implemented cost optimization strategies, focusing in particular on two of our company values: performance and end-consumer care. In doing so, we were able to identify effective ways to control our expenses, even in the context of rising raw material and packaging prices. The Consumer Healthcare category in Romania is becoming more and more competitive year by year, marked also by a slight decline in volumes in 2023 compared to 2022. However, we ended 2023 managing to consolidate our position on the market, with a positive evolution of the volume market share and to contribute positively on the quality of life of patients and consumers in Romania", said Cătălin Vicol, Biofarm CEO.
Biofarm continued to strengthen its market share in the Consumer Healthcare (CHC) segment, and ended 2023 in second position in terms of number of units sold.
The company dominates in value in 6 key categories across brands: Bixtonim, Triferment, Colebil, Extravalerianic, Carmol and Carbocit. In addition, Biofarm is the volume leader in no less than 8 categories, highlighting the outstanding performance of the brands Bixtonim, Colebil, Triferment, Sennalax, Extravalerianic, Carmol, Carbocit and Nervocalmin. These results confirm the success of Biofarm's approach and commitment to innovation. Through its achievements, the company continues to establish itself as a trusted player in Consumer Healthcare, offering effective and affordable solutions to consumers.
Biofarm has two drug factories in Bucharest and a product testing and development unit, and its portfolio of over 100 products covers the most important therapeutic areas of the Consumer Healthcare division (digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system). Constant innovation in the development of new products is one of the fundamental elements for Biofarm's expansion and strengthening its position among the leaders in the pharmaceutical industry.
The information provided by KomuniK
Due to the Pentecost holidays, we will resume our activity tomorrow, 10 06 2025
President Nicusor Dan on Thursday said that all political parties currently engaged in discussions - the Social Deocratic Party (PSD), the National Liberal Party (PNL), the Save Romania Union (USR) and the Hungarian Democratic Union of Romania (UDMR) - want to join the government.'I am very pleased that all the parties engaged in discussions want […]
More than half of Romanians think that PSD, PNL, and UDMR should be included in the next government, according to an INSCOP Research barometer conducted between May 26–30, 2025. “Survey participants were asked to indicate, for each parliamentary party, whether they believe that party should be part of the next government. Thus, 59.5% of […]
Cuda, Sirin and a marine drone are three types of Romanian military UAVs which are set to enter production this year at CARFIL Brasov, a subsidiary of the National Company ROMARM. They were unveiled at the Southeast Europe Special Operations Forces Forum 2025 (SEESOF) in Targu Mures - the first international expo-forum dedicated to the […]
The French Ambassador in Bucharest, Nicolas Warnery, stated, on Thursday, during a press conference, that there was "a systematic disinformation campaign" regarding his country during the presidential elections in Romania."Basically, we have witnessed a systematic disinformation campaign, sometimes with malicious interpretations, with mistakes, with lies, with the aim of harming France. Who is winning […]
Background Romania’s medium-term fiscal framework calls for the fiscal deficit to decline gradually from about 8 percent of GDP in 2024 to 7 percent in 2025 and 3 percent (or less) by 2031. With limited scope for expenditure consolidation ? given the low expenditure-to-GDP ratio ? revenue mobilization is imperative. In the short term, […]